Key Stats for CVS Health Stock
- 52-Week Range: $58.50 – $102.77
- Current Price: $99.16
- Street Mean Target: around $105
- TIKR Mid-Case Model Target (2030): around $129
- Mid-Case Annualized Return: just under 6% per year
- Q1 2026 Revenue: $100.4 billion, up around 6% year over year
- Q1 2026 Adjusted EPS: $2.57, up from $2.25 a year ago
What Changed at CVS Health
A company that spent two straight years cutting its own guidance does not usually trade near a 52-week high. CVS (CVS) got there anyway, and the turnaround traces back almost entirely to Aetna, the insurance arm whose struggles with rising medical costs had been dragging on the stock since 2023.
The first quarter of 2026 was the clearest signal yet that the repair work is paying off. CVS posted revenue of $100.4 billion, up around 6% year over year, and adjusted earnings per share of $2.57 against a Street estimate closer to $2.20, the company’s fifth consecutive beat. Management raised full-year adjusted EPS guidance to a range of $7.30 to $7.50.
The single number that explains most of the move is Aetna’s medical benefit ratio, which fell to 84.6% from 87.3% a year earlier. On a premium base of nearly $34 billion, that swing flows straight to the bottom line, and adjusted operating income in the Health Care Benefits segment jumped more than 50%.
A favorable 2027 Medicare Advantage rate decision from CMS, finalized in April at 2.48% rather than the nearly flat 0.09% initially proposed, removed a multi-year policy overhang on top of that.
CVS also used the quarter to launch Health100, a new subsidiary built with Google Cloud that aims to give consumers a single digital front door across its pharmacy, insurance, and care businesses.
The more interesting bet is that CVS is opening the platform to outside payers and providers as well, positioning itself as healthcare’s connective layer rather than just a tool for its own customers. It is early and not yet material to revenue, but it gives the stock a second narrative beyond the Aetna repair story.
See analysts’ growth forecasts and price targets for CVS (It’s free) >>>
What the Valuation Model Says
This is where the math gets less straightforward than the headlines suggest. With the stock at $99.16, near the top of its 52-week range, TIKR’s mid-case scenario targets $128.77 by the end of 2030, implying a total return of around 30% and an annualized return of just under 6%.
That is a meaningfully tougher path than the one that produced this run, since the model assumes revenue growth slowing to the 4% range annually and a P/E multiple that actually contracts slightly rather than expands from here.
CVS has to earn this return almost entirely through earnings growth, not a richer valuation, which is a different setup than the deeply discounted entry point this stock offered a year ago.
The Street’s mean target sits around $105, only modestly above today’s price, but that consensus has been chasing the stock higher all year, sitting closer to $96 back in March and $72 a year ago.
Eighteen of the 26 analysts TIKR tracks rate the stock a buy, with none rating it a sell. That reflects real conviction in the turnaround, but it also means most of the optimism has already been expressed through upward revisions rather than sitting ahead of the price.
A year ago, when the stock traded in the high $60s, TIKR’s model implied annualized returns well above 30%, a wide enough gap to call the stock genuinely mispriced. At $99, with TIKR’s model at $128.77 and the Street’s mean target at $105, that gap has mostly closed.
See historical and forward estimates for CVS stock (It’s free!) >>>
Should You Invest in CVS Health, Inc.
The bull case is that execution keeps going in the direction it is already headed. Aetna’s MBR improvement looks like real underwriting discipline rather than a one-time comparison, the CMS rate decision gives the insurance business more room than expected, and Health100 offers a credible path to higher-margin platform revenue if it scales.
The bear case is that most of the easy money has already been made. TIKR’s model now implies a mid-single-digit annualized return; medical membership fell as CVS exited the individual exchange business; and a net debt-to-EBITDA ratio of 3.61x limits room for aggressive capital returns while leverage remains elevated.
CVS Health’s turnaround is real, and the swing in Aetna’s medical benefit ratio is among the clearest evidence of execution the company has shown in years. What has changed is not the quality of the business but the price investors are paying for it.
The next test is straightforward. If Aetna’s MBR holds inside its guided range when CVS reports second-quarter results, the recovery extends. If it doesn’t, the current valuation leaves much less room for error than it did a year ago.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
